Brokerages Anticipate Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Will Post Earnings of -$0.75 Per Share

Equities analysts predict that Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLXGet Rating) will announce earnings per share (EPS) of ($0.75) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Amylyx Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.81) and the highest estimate coming in at ($0.68). The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Amylyx Pharmaceuticals will report full-year earnings of ($3.17) per share for the current year, with EPS estimates ranging from ($3.43) to ($2.90). For the next fiscal year, analysts anticipate that the company will report earnings of $0.01 per share, with EPS estimates ranging from ($1.59) to $1.60. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Amylyx Pharmaceuticals.

Several research firms have issued reports on AMLX. Evercore ISI began coverage on shares of Amylyx Pharmaceuticals in a report on Wednesday, February 2nd. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Amylyx Pharmaceuticals in a report on Tuesday, February 1st. SVB Leerink reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Amylyx Pharmaceuticals in a report on Tuesday, February 1st. Finally, The Goldman Sachs Group began coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday, February 1st. They issued a “buy” rating and a $36.00 price target on the stock.

NASDAQ AMLX opened at $9.00 on Friday. The business has a fifty day moving average price of $18.99. Amylyx Pharmaceuticals has a 12-month low of $8.81 and a 12-month high of $33.41.

Amylyx Pharmaceuticals Company Profile (Get Rating)

Amylyx Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases.

Featured Stories

Get a free copy of the Zacks research report on Amylyx Pharmaceuticals (AMLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.